Simeprevir Sodium

西美瑞韦钠

Report date: 2022/05/19 14:21:38
NME

Base Information

Drug NameSimeprevir Sodium
Drug Alias NameSimeprevirum西咪匹韦钠司美瑞韦西米普韦西美瑞韦 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsMeaslesHepatitis C, ChronicHepatitis C +[5] 
Global Approved IndicationsHepatitis C, ChronicHepatitis C
Approved Indications in ChinaHepatitis C
Original Approved Country/TerritoryJapan
Original Approved Date2013/09/27
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson Innovative MedicineMedivir ABJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesJanssen-Cilag International NvJohnson & Johnson
Inactive CompaniesSerum Institute Of India Pvt LtdJanssen Products, LpXian Janssen Pharmaceutical Ltd +[9] 
Active IndicationsHepatitis C
Inactive IndicationsMeaslesHepatitis C, ChronicTuberculosis +[4] 

Other Information

ATC CodeJ05AP05
Related LinksWikipediaDrugBankKEGG